Amarin Corporation (AMRN, Financial) experienced a significant stock movement with a sharp decline of 5.55%. The stock is currently trading at $0.592 per share with a trading volume of 868,036 shares and a turnover rate of 0.21%, showing a price fluctuation amplitude of 8.44%.
Recent financial reports reveal that Amarin generated $42.73 million in revenue but reported a net loss of $25.39 million, resulting in an EPS of -$0.06. The company's gross profit stood at $15.68 million, with a negative P/E ratio of -5.92, indicating financial challenges.
In the broader pharmaceutical industry, where Amarin operates, there has been an overall increase of 2.13%. Notable gainers in the sector include Alpha Teknova, Inc., Su Xuantang, and Citius Oncology, Inc. High activity was observed in stocks like Painreform Ltd., Nature's Sunshine Products, and Su Xuantang, with turnover rates of 56.63%, 9.54%, and 9.21% respectively. Stocks with notable price swings include Brainstorm Cell Therapeutics, Cyclo Therapeutics Inc C/Wts 11/12/2025(To Pur Com), and Alpha Teknova, Inc., with amplitudes of 76.43%, 43.18%, and 30.22% respectively.
Amarin is a biopharmaceutical company focused on developing and commercializing therapeutics to improve cardiovascular health and reduce cardiovascular risk, with its key product being Vascepa.
